Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (CHRO)

Q: What does CUSIP 171126105 represent in this 13F holders report?

CUSIP 171126105 is the security identifier for CHRO - Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held CHRO - Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share in Q2 2025?

5 institutional investors reported CHRO - Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share for Q2 2025. Use the holders table for investor-level position and value details.

CUSIP: 171126105

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 6,039,027
Total 13F shares: 147,903
Share change: -447,942
Total reported value: $187,297
Price per share: $1.26
Number of holders: 5
Value change: -$657,522
Number of buys: 3
Number of sells: 6

Quarterly Holders Quick Answers

What is CUSIP 171126105?
CUSIP 171126105 identifies CHRO - Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2025
Previous quarter: Q1 2025

Recent filing periods for CUSIP 171126105:

Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024

Top shareholders of CHRO - Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

No top shareholder records were found across 13F, 13D/G, and Forms 3/4/5 for this issuer.

Institutional Holders of Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (CHRO) as of Q2 2025

As of 30 Jun 2025, Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (CHRO) was held by 5 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 147,903 shares. The largest 5 holders included MILLENNIUM MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, UBS Group AG, Tower Research Capital LLC (TRC), and BANK OF AMERICA CORP /DE/. This page lists 5 institutional shareholders reporting positions in this security for the Q2 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders

Q2 2025 holders

Holder diff

-3

Investor	Q1 2025 Shares	Q2 2025 Shares	Share Diff	Share Chg %	Q1 2025 Value $	Q2 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.